MIST Valuation

Milestone Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

1.690

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

MIST Relative Valuation

MIST's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MIST is overvalued; if below, it's undervalued.

Historical Valuation

Milestone Pharmaceuticals Inc (MIST) is now in the Fair zone, suggesting that its current forward PS ratio of 279.73 is considered Fairly compared with the five-year average of -3.09. The fair price of Milestone Pharmaceuticals Inc (MIST) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：1.67

Fair

-1.59

Trailing

Forward

0.00

EV/EBITDA

Milestone Pharmaceuticals Inc. (MIST) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.10. The thresholds are as follows: Strongly Undervalued below -3.80, Undervalued between -3.80 and -2.95, Fairly Valued between -1.26 and -2.95, Overvalued between -1.26 and -0.41, and Strongly Overvalued above -0.41. The current Forward EV/EBITDA of 0.00 falls within the Strongly Overvalued range.

-2.89

EV/EBIT

Milestone Pharmaceuticals Inc. (MIST) has a current EV/EBIT of -2.89. The 5-year average EV/EBIT is -1.74. The thresholds are as follows: Strongly Undervalued below -3.13, Undervalued between -3.13 and -2.44, Fairly Valued between -1.05 and -2.44, Overvalued between -1.05 and -0.35, and Strongly Overvalued above -0.35. The current Forward EV/EBIT of -2.89 falls within the Undervalued range.

279.73

Milestone Pharmaceuticals Inc. (MIST) has a current PS of 279.73. The 5-year average PS is 49.04. The thresholds are as follows: Strongly Undervalued below -138.56, Undervalued between -138.56 and -44.76, Fairly Valued between 142.84 and -44.76, Overvalued between 142.84 and 236.64, and Strongly Overvalued above 236.64. The current Forward PS of 279.73 falls within the Strongly Overvalued range.

-2.34

P/OCF

Milestone Pharmaceuticals Inc. (MIST) has a current P/OCF of -2.34. The 5-year average P/OCF is -4.07. The thresholds are as follows: Strongly Undervalued below -7.01, Undervalued between -7.01 and -5.54, Fairly Valued between -2.61 and -5.54, Overvalued between -2.61 and -1.14, and Strongly Overvalued above -1.14. The current Forward P/OCF of -2.34 falls within the Overvalued range.

-6.01

P/FCF

Milestone Pharmaceuticals Inc. (MIST) has a current P/FCF of -6.01. The 5-year average P/FCF is -3.37. The thresholds are as follows: Strongly Undervalued below -34.06, Undervalued between -34.06 and -18.71, Fairly Valued between 11.98 and -18.71, Overvalued between 11.98 and 27.32, and Strongly Overvalued above 27.32. The current Forward P/FCF of -6.01 falls within the Historic Trend Line -Fairly Valued range.

Milestone Pharmaceuticals Inc (MIST) has a current Price-to-Book (P/B) ratio of -6.36. Compared to its 3-year average P/B ratio of 1.95 , the current P/B ratio is approximately -425.66% higher. Relative to its 5-year average P/B ratio of 2.03, the current P/B ratio is about -414.12% higher. Milestone Pharmaceuticals Inc (MIST) has a Forward Free Cash Flow (FCF) yield of approximately -24.29%. Compared to its 3-year average FCF yield of -35.41%, the current FCF yield is approximately -31.41% lower. Relative to its 5-year average FCF yield of -28.46% , the current FCF yield is about -14.67% lower.

-6.32

P/B

Median3y

1.95

Median5y

2.03

-24.29

FCF Yield

Median3y

-35.41

Median5y

-28.46

Competitors Valuation Multiple

The average P/S ratio for MIST's competitors is 47.39, providing a benchmark for relative valuation. Milestone Pharmaceuticals Inc Corp (MIST) exhibits a P/S ratio of 279.73, which is 490.21% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

MIST.O

Milestone Pharmaceuticals Inc

Inhibikase Therapeutics Inc

Loss

137.11M

ACHV.O

Achieve Life Sciences Inc

Performance Decomposition

Market capitalization of MIST increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of MIST in the past 1 year is driven by Unknown.